



# SINO SECURITIES INTERNATIONAL LIMITED



Address: 3<sup>rd</sup> Floor, 43-51 Queen Street  
Melbourne, VIC 3000, Australia

ABN 99 006 620 739

Sino Investment Services Pty Ltd (ABN 49 006 643 152)

Sino Business Services Pty Ltd (ABN 29 006 923 397)

SSI Nominees Pty Ltd (ABN 31 006 724 956)

Sino Investments Pty Ltd (ABN 47 006 643 143)

Sino Asset Management Pty Ltd (ABN 61 007 282 797)

Sino Finance Portal Pty Ltd (ABN 32 086 928 396)

Telephone: (61) 3 9629 6615

Facsimile: (61) 3 9614 1946

E-Mail: [info@sino.com.au](mailto:info@sino.com.au)

Web Site: <http://www.sino.com.au> <http://www.myprofit.com.au>

## INVESTMENT BANKERS

6 February 2002

No of pages: - 2 -  
(including this page)

Australian Stock Exchange  
Company Announcements Platform

Dear Sir/Madam

### **Re: Sino Securities establishing its business interest in Chinese medicine**

The Board of Directors of Sino Securities International Ltd (“SSI”) is pleased to advise that SSI and Professor Tzi Chiang Lin have entered into a ‘Deed of Transfer of Medication’ Agreement (“Agreement”) for the transfer of certain Intellectual Property that belongs to Professor T C Lin to Pharmasafe Pty Ltd (“Pharmasafe”). Under the Agreement, Pharmasafe will be owned as to 60 per cent by Professor T C Lin and 40 per cent by SSI.

Pharmasafe has been established by Professor T C Lin and SSI for the purposes of owning the rights and entitlements to the Intellectual Property transferred by Professor T C Lin to Pharmasafe, manufacturing or licensing the manufacturing of Chinese medicines for which Pharmasafe has secured the Intellectual Property, and marketing and distribution of the medications throughout Australia and internationally.

The primary focus of Pharmasafe will be the commercialization of the Intellectual Property belonging to Professor T C Lin covering a number of major diseases including Hepatitis B and Arthritis. Professor T C Lin will also be assisting Pharmasafe in identifying and securing the marketing and distribution rights of other appropriate Chinese medications, which are based on natural remedies for the Western markets.

SSI will be providing its investment banking services to Pharmasafe. Under the Agreement, SSI will also procure its subsidiary company, GoConnect Ltd, to enter into an agreement with Pharmasafe for the exclusive marketing and distribution of the Chinese medicinal products of Pharmasafe on the Internet throughout the world through its portals and affiliates. SSI will also procure GoConnect Ltd to grant access to the use of the GoTrek technology for the promotion of the Pharmasafe products on the Internet.

Professor T C Lin has been a practitioner and researcher of Chinese medicine for close to 30 years. He is highly regarded in the field of Chinese medicine and acupuncture by the Australian Federal and Victorian governments as well as by the relevant medical authorities and medical research institutions in the People’s Republic of China (“PRC”).

The Board of SSI is delighted with this opportunity to not only add significant value to shareholders, but also to enable the wider application of Chinese medicine to benefit patients affected by various major diseases. The uses of natural remedy and Chinese medicine have gained increasing acceptance and popularity in the last 10 years in the West. SSI and Professor T C Lin, with his substantial knowledge of Chinese medicine, have joined forces in order to effectively promote the uses of Chinese medicine to the West, and to market the products to be derived from Professor T C Lin's Intellectual Property, in order to successfully establish the business of Pharmasafe.

Yours sincerely

Richard Li  
Managing Director  
Sino Securities International Ltd

***About Professor T C Lin***

Professor T C Lin is the National President of the Federation of Chinese Medicine and Acupuncture Society of Australia and has served in that capacity since 1991. He was appointed a member of the Complementary Medicine Evaluation Committee by the Federal Parliament Secretary for Health and Aged Care and served on the Committee from 1997 to 1999. He was a member of the Ministerial Advisory Committee on Chinese Medicine to the Victorian Health Minister between 1997 and 1999. He is the Visiting Professor of Medicine to: the Chinese Academy of Traditional Chinese Medicine in Beijing, the Nanjing University of Traditional Chinese Medicine in Nanjing, and the Weifang Medical College in Weifang City, of the PRC. He was a co-founder of the RMIT University Chinese Medicine Unit in 1992 when he acted in the capacity of Chairman of the Chinese Medicine Development Committee of RMIT. RMIT University is the first university in the Western world, which has established a formal higher educational degree course in Chinese medicine. He has been responsible for the publication of five books and numerous research papers on Chinese medicine and acupuncture.